

### REMARKS

Claims 1-11 have been rewritten as claims 12-22 To conform to US practice. There is no new matter added, and entry of the amendment is respectfully requested.

Applicants enclose a paper copy and a computer readable form of a Sequence Listing. The content of the paper copy and of the computer readable form is the same. This submission contains no new matter.

The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this amendment or application.

Respectfully submitted,

Date: April 11, 2005

  
Elias J. Lambiris, Reg. No. 33,728  
Novozymes North America, Inc.  
500 Fifth Avenue, Suite 1600  
New York, NY 10110  
(212) 840-0097